A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy Participants

Inclusion Criteria:

• Male and female participants who are healthy as determined by the investigator basedon review of medical history, physical examinations, 12-lead ECGs, and clinicallaboratory tests obtained during the screening period.

• Participant is willing and able to adhere to the study visit schedule and otherprotocol requirements.

• A negative test for COVID-19, which will be performed in the manner mandated by theclinical site where this study is being conducted, at screening and admission.

Exclusion Criteria:

• Evidence of organ dysfunction or any clinically significant deviation from normal inphysical examination, vital signs, 12-lead ECG, or clinical laboratory tests beyondwhat is consistent with a healthy population in the region in which the study isconducted.

• Participant was exposed to an investigational drug (new chemical entity) within 30days preceding the first dose administration, or 5 half-lives of thatinvestigational drug, if known (whichever is longer).

• Inability to be venipunctured or tolerate venous access.

Note: Other protocol-defined inclusion/exclusion criteria apply